IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : C.J.M. MEADE, et al. U.S. Appln. No. : Not Yet Assigned Confirmation No. : Not Yet Assigned U.S. Filing Date : Not Yet Assigned Title of Invention : NEW PHARMACEUTICA ANTICHOLINERGICS AND Attny. Docket No. : 1/1460 PCT) Examiner: AL COMPOSITIO	NS BASED ON	
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	·		
August 2, 2005			
TRANSMITTAL LETTER FOR INFOR	MATION DISCL	OSURE STATEMENT	
Sir:			
Transmitted herewith concerning the subject ap Statement (Form 1449A/B) under 37 C.F.R. §§ hereinbelow.			
1.97(b). This Statement is being f date of a national application other than a contin §1.53 (d); ii) within three (3) months of the date 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114.	nued prosecution a e of entry of the na e; iii) before the ma t Office action after	tional stage as set forth in ailing of a first Office action	
1.97(c). This Statement is being f C.F.R. §1.97(b), but before the mailing date of: notice of allowance under 37 C.F.R. §1.311, or in the application. This Statement is being account.	i) a final action ur iii) an action that	nder 37 C.F.R. §1.113, ii) a	
A statement as specified in 37 C	C.F.R. §1.97(e) [se	e below]; or	
The fee set forth in 37 C.F.R. 81	17(n)		

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
•	ent as sp	This Statement is being filed after the period specified in 37 C.F.R. or before payment of the issue fee. This Statement is accompanied by a ecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)	
	counter	Each item of information contained in the instant information disclosure nt was first cited in any communication from a foreign patent office in a part foreign application not more than three (3) months prior to the filing of ant information disclosure statement; or
	foreign making informations §1.56(c	No item of information contained in the instant information disclosure nt was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after reasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 C.F.R.) more than three (3) months prior to the filing of the instant information are statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosi counter in section	part ap on 1.56	Each item of information contained in the accompanying information ment was cited in a communication from a foreign patent office in a dication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying closure statement

JC09 Poc'd PCT/PTO 02 AUG 2005

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Andrea D. Small

Attorney for Applicant(s)

Reg. No. 54,859

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4816 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 2, 2005.

Andrea D. Small, Reg No. 54,859

10/544238 JC09 Rec'd PCT/PTO 12 AUG 2005

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1/1460 PCT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number Not Yet Assigned Filing Date INFORMATION DISCLOSURE Not Yet Assigned First Named Inventor Christopher J.M. MEADE STATEMENT BY APPLICANT Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned (Use as many sheets as necessary)

Sheet

Attorney Docket Number

			U.S.PA						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication MM-DD-YY			ame of Patentee or ant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear) it
		^{US-} 2002/193394	12/19/2002	***************************************	Bernd	DISSE			
		^{US-} 2004/039011	02/26/2004		Bernd	DISSE		······································	
		US-	·						
****		US-							
		US-		· · · · · · · · · · · · · · · · · · ·			İ		_
		US-						aladina ki maren diri diri diri dan dalam yaya mayo ila kada a santa dan dan dan kada da dan dan dan dan dan d	
***************************************		US-							
		us-							
		US-							••••
		US-					ļ		
		US-		······································					
		US-)Mala			
		US-							
		US-							
		US-							••••
······	***************************************	US-							
		US-		***************************************					••••
····		US-					ļ		
			FOREIGN P	ATENIT	DOCI	IMENTS		<u> </u>	=
			FOREIGNE	AIENI	DOCC	MIENTS			T
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication Date Name of Patentee or MM-DD-YYYY Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages		
iiiiidis	140.	Country Code ³ 'Number ⁴ 'Kind Code ⁵ (if known)			Applicant of Cited Docum		ine iii	or Relevant Figures Appear	┛
	WO 02/072095			09/19/2002		Boehringer Ingelheim Pharma KG			
					**************	••••••			1
					••••••				4

		10.000		
Examiner	1 1001		Date	
Signature			Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/544238 JC09 Rec'd PCT/PTO Q2 AUG 2005

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	Stitute for form 1449B/PTO NFORMATION DISCLOSUR TATEMENT BY APPLICAN (Use as many sheets as necessary)		Complete if Known				
				Application Number	Not Yet Assigned		
INFOR	MATION [DISCLO	SURE	Filing Date	Not Yet Assigned		
STATEMENT BY APPLICANT		First Named Inventor	Christopher J.M. MEADE				
				Art Unit	Not Yet Assigned		
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	•	
Sheet	2	of	2	Attorney Docket Number	1/1460 PCT		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		D.J.HELE, et al. "Novel therapies for the treatment of inflammatory airway disease" Expert Opinion on Investifational Drugs, Ashley Publications Ltd. Vol.12, No. 1, 2003, pp 5-18 XP009014907	
		A. TRIFILIEFF, et al. "Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation", British J. Pharmacology 2002; 135; pp1655-1664 XP001202131	
		T.T.HANSEL, et al. "Tiotropium Bromide: A Novel Once-Daily Anticholinergic Bronchodilator for the Treatment of COPD" Drugs of Today, 2002; 38; (9); pp585-600 XP009022208	
		C-B. XUE, et al. "Design, Synthesis, and Structure - Activity Relationships of Macrocyclic Hydroxamic Acids that Inhibit Tumor Necrosis Factor alpha Release in Vitro and in Vivo" J. Med. Chem. 2001; 44; pp2636-2660 XP001199586	
			••••••
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.